KR20170069262A - Smad7 안티센스 올리고뉴클레오티드로 대상체를 치료하기 위한 방법 및 조성물 - Google Patents

Smad7 안티센스 올리고뉴클레오티드로 대상체를 치료하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20170069262A
KR20170069262A KR1020177012839A KR20177012839A KR20170069262A KR 20170069262 A KR20170069262 A KR 20170069262A KR 1020177012839 A KR1020177012839 A KR 1020177012839A KR 20177012839 A KR20177012839 A KR 20177012839A KR 20170069262 A KR20170069262 A KR 20170069262A
Authority
KR
South Korea
Prior art keywords
smad7
day
antisense oligonucleotide
patient
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177012839A
Other languages
English (en)
Korean (ko)
Inventor
지오반니 몬텔레온
Original Assignee
노그라 파마 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노그라 파마 리미티드 filed Critical 노그라 파마 리미티드
Publication of KR20170069262A publication Critical patent/KR20170069262A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177012839A 2014-10-17 2015-10-16 Smad7 안티센스 올리고뉴클레오티드로 대상체를 치료하기 위한 방법 및 조성물 Withdrawn KR20170069262A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462065598P 2014-10-17 2014-10-17
US62/065,598 2014-10-17
PCT/EP2015/074066 WO2016059239A1 (en) 2014-10-17 2015-10-16 Methods and compositions for treating a subject with a smad7 antisense oligonucleotide

Publications (1)

Publication Number Publication Date
KR20170069262A true KR20170069262A (ko) 2017-06-20

Family

ID=54330761

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177012839A Withdrawn KR20170069262A (ko) 2014-10-17 2015-10-16 Smad7 안티센스 올리고뉴클레오티드로 대상체를 치료하기 위한 방법 및 조성물

Country Status (12)

Country Link
US (2) US10337004B2 (enrdf_load_stackoverflow)
EP (1) EP3207136A1 (enrdf_load_stackoverflow)
JP (1) JP2017532961A (enrdf_load_stackoverflow)
KR (1) KR20170069262A (enrdf_load_stackoverflow)
CN (1) CN107406851A (enrdf_load_stackoverflow)
AU (1) AU2015332624A1 (enrdf_load_stackoverflow)
CA (1) CA2964667A1 (enrdf_load_stackoverflow)
EA (1) EA201790867A1 (enrdf_load_stackoverflow)
IL (1) IL251717A0 (enrdf_load_stackoverflow)
MA (1) MA43331A (enrdf_load_stackoverflow)
MX (1) MX2017004973A (enrdf_load_stackoverflow)
WO (1) WO2016059239A1 (enrdf_load_stackoverflow)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
EP3121280B1 (en) 2008-11-13 2025-04-09 Nogra Pharma Limited Antisense compositions and methods of making and using same
CA2848595A1 (en) 2011-09-15 2013-03-21 Nogra Pharma Limited Methods for monitoring responsiveness to anti-smad7 therapy
IN2014DN08158A (enrdf_load_stackoverflow) 2012-04-18 2015-05-01 Nogra Pharma Ltd
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
KR20170005058A (ko) 2014-05-09 2017-01-11 노그라 파마 리미티드 염증성 장 질환을 치료하는 방법
JP2017532961A (ja) 2014-10-17 2017-11-09 ノグラ ファーマ リミテッド Ｓｍａｄ７アンチセンスオリゴヌクレオチドによる対象を処置するための方法および組成物
JP2017537973A (ja) * 2014-10-17 2017-12-21 ノグラ ファーマ リミテッド バイオマーカーレベルを使用してｓｍａｄ７アンチセンスオリゴヌクレオチドを投与するおよびモニタリングするための方法
WO2017147276A1 (en) 2016-02-23 2017-08-31 Celgene Corporation Methods of treating intestinal fibrosis using smad7 inhibition
EP3562943A1 (en) * 2016-12-30 2019-11-06 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis
MX2022013261A (es) * 2020-04-24 2022-11-14 Nogra Pharma Ltd Composiciones de oligonucleotidos antisentido (aso) contra smad7 y metodos para usar las mismas.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1456380E (pt) 2001-11-02 2012-07-23 Giuliani Int Ltd Inibidores smad7 para o tratamento de doenças do snc
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
EP3121280B1 (en) 2008-11-13 2025-04-09 Nogra Pharma Limited Antisense compositions and methods of making and using same
NZ594281A (en) * 2009-01-26 2013-09-27 Academisch Ziekenhuis Leiden Means and methods for modulating notch3 protein expression and/or the coding region of notch3; compositions and use thereof in the treatment of cadasil
EP3208347B1 (en) * 2010-02-08 2019-08-14 Ionis Pharmaceuticals, Inc. Selective reduction of allelic variants
CA2848595A1 (en) 2011-09-15 2013-03-21 Nogra Pharma Limited Methods for monitoring responsiveness to anti-smad7 therapy
IN2014DN08158A (enrdf_load_stackoverflow) 2012-04-18 2015-05-01 Nogra Pharma Ltd
KR102232623B1 (ko) 2013-03-15 2021-03-26 노그라 파마 리미티드 결장직장암의 치료 방법
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
KR20170005058A (ko) * 2014-05-09 2017-01-11 노그라 파마 리미티드 염증성 장 질환을 치료하는 방법
JP2017537973A (ja) 2014-10-17 2017-12-21 ノグラ ファーマ リミテッド バイオマーカーレベルを使用してｓｍａｄ７アンチセンスオリゴヌクレオチドを投与するおよびモニタリングするための方法
JP2017532961A (ja) 2014-10-17 2017-11-09 ノグラ ファーマ リミテッド Ｓｍａｄ７アンチセンスオリゴヌクレオチドによる対象を処置するための方法および組成物
EP3207135A2 (en) 2014-10-17 2017-08-23 Celgene Alpine Investment Company II, LLC Isotopologues of smad7 antisense oligonucleotides
MA41271A (fr) 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
WO2017059225A1 (en) 2015-09-30 2017-04-06 Celgene Corporation Tlr modulators and methods of use
EP3355896A2 (en) 2015-09-30 2018-08-08 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression

Also Published As

Publication number Publication date
AU2015332624A1 (en) 2017-05-04
CA2964667A1 (en) 2016-04-21
US20170240893A1 (en) 2017-08-24
EA201790867A1 (ru) 2017-08-31
MX2017004973A (es) 2017-12-07
MA43331A (fr) 2017-08-23
CN107406851A (zh) 2017-11-28
US10337004B2 (en) 2019-07-02
US20190338283A1 (en) 2019-11-07
WO2016059239A1 (en) 2016-04-21
JP2017532961A (ja) 2017-11-09
EP3207136A1 (en) 2017-08-23
IL251717A0 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
US10337004B2 (en) Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
KR102622309B1 (ko) 염색체 상호작용의 검출
CN101892311B (zh) 高血压易感基因的单核苷酸多态性位点rs7550536的检测方法及检测试剂盒
CN107530431B (zh) 生物标志物
US20170233736A1 (en) Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
WO2018231851A1 (en) Methods of treating liver fibrosis
EP3615694B1 (en) Il-8, il-6, il-1b and tet2 and dnmt3a in atherosclerosis
TW201326399A (zh) 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定
WO2017055611A2 (en) Methods of using smad7 antisense oligonucleotides based on biomarker expression
EP3638246A1 (en) Diagnostic and therapeutic methods for irak4-mediated disorders and conditions
KR20210084528A (ko) I형 인터페론 시그너처 및 사용 방법
US20210207143A1 (en) Methods of Treating Celiac Disease Using SMAD7 Inhibition
Stapleton et al. Using omics to explore complications of kidney transplantation
CA3121162A1 (en) Rnaset2 compositions and methods of treatment therewith
Di Meglio et al. Immunopathogenesis of psoriasis
US20140161769A1 (en) Methods for treating inflammatory autoimmune disorders
US20230287499A1 (en) Methods and systems for measuring post-operative disease recurrence
CN116322774A (zh) 单核苷酸多态性和炎性病状的治疗
CN101886129B (zh) 高血压易感基因AGTR1单核苷酸多态性位点rs388915的检测方法及检测试剂盒
KR101611004B1 (ko) ＴｒｋＡ를 이용한 백혈병 진단용 조성물
EP3420082A1 (en) Methods of treating intestinal fibrosis using smad7 inhibition
WO2010084668A1 (ja) ネフローゼ症候群の検査方法、並びにネフローゼ症候群の予防又は治療薬およびそのスクリーニング方法
KR102202120B1 (ko) 알츠하이머 질환의 진단 또는 치료를 위한 Ｕｂｅ２ｈ의 용도
WO2008041767A1 (fr) Marqueur de gène ou de protéine utilisé pour la prévision ou le diagnostic de l'efficacité pharmacologique d'un inhibiteur d'aurora a
JP4869834B2 (ja) 抗ヒトＴＮＦαキメラ抗体を含有する薬剤に対する副作用に関連する多型、およびその利用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170512

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination